Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD study of sunitinib and pazopanib in metastatic renal cell carcinoma
NL-OMON40825Phase 4Recruiting
- Sponsor
- Leiden University Medical Center
- Start
- Jul 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of sunitinib and pazopanib in renal cell carcinoma (RCC) (2 arms), sponsored by Leiden University Medical Center. Primary endpoints: Development of PK/PD model for sunitinib and pazopanib, Blood pressure biomarker assessment and 2 more. Started Jul 2014; status: recruiting.
02
Drugs
sunitinibpazopanib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NL-OMON40825.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40825.